HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDER review management

This article was originally published in The Rose Sheet

Executive Summary

Drug center Director Janet Woodcock, MD, takes on additional role as acting director of CDER's Office of Review Management following the resignation of Murray Lumpkin, MD. Lumpkin will remain at FDA "on detail to a deputy center director position for the next several weeks to assist me in the ORM transition," Woodcock told CDER staff in an Oct. 13 memo. During that time, Lumpkin will evaluate "various options outside the center." His resignation was for personal reasons, according to the memo. During his tenure as the ORM head, Lumpkin contributed to the creation and ongoing implementation of the OTC labeling reg

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel